Target Markets

The Syntopix vision is to create a range of new antimicrobial opportunities that target three distinct markets in the next three to five years:

• consumer healthcare;
• over the counter treatments; and
• prescription medicines for acne and the treatment and control of infections including those due to MRSA.

Many consumer healthcare products rely on antimicrobial solutions and the Syntopix approach provides novelty in many of these areas. For example, the global anti-dandruff shampoo market is estimated to be worth $20 billion whilst oral healthcare generates over $24 billion in sales per annum.

Globally the prescription dermatology market is worth around $16 billion with sales for topical medicinal acne products exceeding $2.5 billion. Cosmetic acne product sales are currently in excess of $10 billion.

The market for the topical treatment and prophylaxis of S. aureus infection and carriage is approximately $0.5 billion and is predicted to increase, partly in response to the awareness of MRSA as a community pathogen.

Market Drivers

Strong market pressures are increasing demand for novel antimicrobial solutions across each of Syntopix's target markets. These pressures are:

• increasing antibiotic resistance;
• environmental pressure on existing antimicrobials due to the link between overuse of biocides and antibiotic resistance; and
• trend towards 'cosmeceuticals'.

COPYRIGHT 2008 SYNTOPIX GROUP PLC, SYNTOPIX IS A REGISTERED TRADEMARK ACCESSIBILITY STATEMENT SITE MAP TEXT ONLY VERSION TERMS & CONDITIONS